Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs.
Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied after a study showed the weight-loss and diabetes drugs reduced the risk of developing Alzheimer's.
Investment firm Bain Capital is in talks to acquire Mitsubishi Chemical Group's pharmaceutical business in a potential multibillion-dollar deal, a transaction that could accelerate the Japanese chemical giant's efforts to focus on key businesses.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
January 21, 2025 17:25 ET (22:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。